Glaxosmithkline Beecham Case Study

Great Essays
SYNTHESIS
Problem Identification/Issues

The merger between SmithKline Beecham and Glaxo Wellcome came about as both companies had poor returns to Research and Development (R&D) investment even though sharp increases in spending on we made in both companies. One GlaxoSmithKline (GSK) was formed they were under pressure as patents were on the verge of expiration and there were a lack of new drugs on the market. As it related management, there was a carry-over is issue with regards to Wellcome having laissez-faire management style which saw them operating unconscious of budget control whilst Glaxo was uncompromising, optimal profit and control-driven in nature. Analysts were therefore concerned whether their merger produced any synergies at
…show more content…
Capabilities are formed when resources are integrated to achieve specific goals. Pharmaceutical companies merge with the intent to create economies of scale that fund research and development budgets. The matrimony between Glaxo Wellcome and SmithKline manifested due to the industry indicating its great need for critical mass in R&D and global marketing presence in order to gain competitive advantage for any one company. Patents can effectively protect proprietary technology the pharmaceutical industry. As such, GlaxoSmithKline when formed was more assured of an income stream by patent protection as a singular drug didn’t account for greater than 12% of revenue and leading up to the merger only 7% of Glaxo Wellcome’s revenue came from drugs that had US patents expiring earlier than 2006 in contrast to SB’s 33%.
II. The company has grown greatly in Central and Eastern Europe. Their share price had rocketed and associated costs to maintain and grow their presence in these markets such as marketing of new products were growing quickly as well. It was important for them to expand globally as a first-rate competitor cannot conduct all its operations from only their US home market that represented 6 to 8 per cent of its existence. The US accounted for 45% of the global pharmaceutical market so growth was more feasible on a global
…show more content…
Beecham and SmithKline Beckman both felt threatened as potential takeover targets hence their merger. Glaxo’s hard-nosed culture however, prevailed over Wellcome’s compassionate style. Fewer former Wellcome executives carried over from the takeover to form Glaxo Wellcome. Senior managers of GlaxoSmithKline (GSK) need to pay keen attention when developing their own culture. Regulatory delays consumed over 10 months of negotiations which backtracked the merger process twice and would have put of this activity. It however needs to be done thoughtfully and in a timely manner so as to have the GSK benefit from economies of scale in the reduce costs and potential payoffs that could manifest from harmonizing the merged companies’ research skills. A supportive culture was formed as Garnier and others in senior management made efforts to get closer to employees via their method of correspondence. Members from each of the previous teams felt efforts to unite both cultures were being

Related Documents

  • Superior Essays

    Purinex Case Study

    • 1463 Words
    • 6 Pages

    “The partnership, if secured, would enable Purinex to develop one of its leading compounds into drug for the treatment of one of the world’s deadliest and most widespread diseases.” The problem is the company had only enough cash and had not sales. The CFO of Purinex, Gilad Harpaz thought that if a partnership deal survive, the Purinex might be in perfect situation to fulfill its work. “Harpaz thought that the company could either try secure financing now or wait until struck a partnership deal. The company had a lot of comprehensive technologies was under evolution, and had a suitable partnership deal one for sepsis and the second one is for diabetes.…

    • 1463 Words
    • 6 Pages
    Superior Essays
  • Improved Essays

    In addition, pharmaceutical industry is getting more competitive due to more merge companies and harder to get product approval by FDA. In addition, the number of new IND application is increasing in every fiscal year and FDA does not ease the regulatory or expedite the NDA review…

    • 544 Words
    • 3 Pages
    Improved Essays
  • Decent Essays

    Discussion Board # 3 Reply 3 Johan Rivera Liberty University Perkins Thank you for investing time with the Wellcome- Glaxo and Ofra Sherman case. You provided relevant information about the situation Ofra Sherman faced and how she deals with it. In the introduction, you mentioned that changes in organizations are constantly happening whether is increasing job opportunities or decreasing salaries in order to implement new strategies that are going to benefit the organization as a whole. This was the case with Wellcome and Glaxo, however, they tried to incorporate changes without communicating a strategy for it. “As an enterprise looks to make a significant change within, it is important to have a plan of action which takes into account the definition…

    • 362 Words
    • 2 Pages
    Decent Essays
  • Great Essays

    Situation Analysis: 5C’s One environment factor that provides opportunities for Allstar Allround brand is recommendations from doctors and physicians. These recommendations can increase this company’s market share, net income, and brand awareness. Allround brand offers 4- Hr. Multi Liquid medication.…

    • 1116 Words
    • 4 Pages
    Great Essays
  • Decent Essays

    Bill Jenison, president of Pharmacy Gold, said the pharmaceutical company-PBM mergers will allow his independent PBM to "leverage more enrollment because of our clinical objectivity and independence." With existing PBMs prepared to handle increased market share, and new PBMs forming, the arguments that the manufacturer-PBM mergers increase the barriers to entry into the industry, or foreclose unique products or services, are weakened. Additionally, no pharmaceutical company makes every drug on a formulary list, so the possibility of strict foreclosure is diminished because the PBMs must maintain supplier relationships with other manufacturers. A different issue arises from these continued supplier relationships concerning more subtle ways in which…

    • 6621 Words
    • 27 Pages
    Decent Essays
  • Superior Essays

    Below is a chart that shows how technology and productivity have helped increase the revenue of Pharmaceutical companies in the last five years. One would notice that with the increase in technology, the revenue generated by this industry has been on the high rise. Thus allowing the companies to explore better ways of improving their products. That is to say, the table shows how the increase in money has been able to aid companies in the research and development aspect. Effects of the United States monetary policy and fiscal policy on the financial performance of Johnson and Johnson…

    • 1251 Words
    • 5 Pages
    Superior Essays
  • Decent Essays

    The first challenge is going to be passing the Section 2 of the Sherman Act, which is designed to attack monopolies, due to the fact that if they combine, they will have power to fix prices or exclude competitors from a pharmaceutical market. However, the Section 2 considers the act of monopolizing, thus, their monopoly power, which resulted from combination, is not enough to be guilty because there must be an intent to monopolize the market. For this reason, Pfizer and Allergen should convince the court that they will be acquired a dominant market position through superior products or other demos. Another challenge will be the Section 7 of The Claytn Act, which designed to attack to mergers, but the court considers horizontal merger (between…

    • 136 Words
    • 1 Pages
    Decent Essays
  • Improved Essays

    1960s Thalidomide Scare

    • 1072 Words
    • 5 Pages

    In 1956, the German pharmaceutical company, Chemi Grunenthal, had ostensibly struck gold (Rehman et el. 2011). They had marketed the latest “blockbuster drug,”…

    • 1072 Words
    • 5 Pages
    Improved Essays
  • Great Essays

    Background of Client Downturn “We were a proud company with a constant stock market growth, the master of our destiny. Suddenly, we were raided.” By Herminia Ibarra and Nicole Sackley, “Charlotte Beers at Ogilvy & Mather Worldwide”, 2011 HBS The mass client exodus from O&M began as early as 1989 when WPP Group Plc, a leading marketing services company, acquired Ogilvy & Mather and merged with previously acquired J. Walter Thompson.…

    • 1074 Words
    • 5 Pages
    Great Essays
  • Improved Essays

    FDA identifies three faults in production process, less control on production and process, improper maintenance of equipments and un-updated computer systems (U.S. Food and Drug Administration). Due to the shutdown of production of their best-selling products, Genzyme tumble its share prices. Due to these situations company became more susceptible and sought for a takeover. As a result, Sanofi, pharmaceutical company acquired Genzyme for a total consideration of $20.1 billion in February…

    • 981 Words
    • 4 Pages
    Improved Essays
  • Improved Essays

    As Pfizer and Johnson & Johnson were among the top ten companies, the total revenue generated in 2016 is equivalent to 5.2 percent of the market value. Firstly, as Pfizer, Inc, the world’s second largest pharmaceutical company, the New York City-based company only had generated approximately 53 billion US dollars of the total revenue. This reflects the vulnerability of Pfizer towards the local economy because the major production of well-known drugs were carried out within US such as Lipitor, Lyrica, Enbrel and Viagra. In addition, with an extensive level of research and development within and outside of US, Pfizer is exposed to global economy where 60 percent of its total revenue, almost 26.4 billion dollars were generated from abroad. To illustrate, Pfizer has over 500 subsidiaries including research and developments departments and manufacturing companies and also with the total 98,000 employees in operations throughout the world.…

    • 826 Words
    • 4 Pages
    Improved Essays
  • Great Essays

    esentation analyses the events leading up to the 2004 merger between the pharmaceutical companies Sanofi-Synthelabo and Aventis. It reveals the social, commercial and political complexities and challenges of a merger process in which the defence of French national interests and regional capabilities competed with traditional ‘commercial’ narratives before the deal was closed. presentation critically evaluates the competing criteria adopted by government and industry to justify different merger scenarios and considers the implications for pharmaceutical innovation, industry consolidation and M&A theory The American economy greatest market for the pharmaceutical industry in 2004 the tax cuts and the lower interest rates stimulated expansion…

    • 1499 Words
    • 6 Pages
    Great Essays
  • Great Essays

    Epipen Case Study

    • 1781 Words
    • 8 Pages

    In turn, pharmaceutical prices have also increased, as seen with the price of the EpiPen. Furthermore, a study done by the Congressional Budget Office emphasizes the lack of the output of new drugs in recent years, which highlights the need for an increase in further research and development (“Research and Development,” 2006). This being said, society’s need for new, innovative pharmaceuticals is only possible through further research and development, which requires sufficient funding from pharmaceutical companies that is attained through drug…

    • 1781 Words
    • 8 Pages
    Great Essays
  • Superior Essays

    Pharmaceutical industries do many great things for our people of America although if they provided us with more sincere information we would probably have better medication and health for our…

    • 2274 Words
    • 10 Pages
    Superior Essays
  • Great Essays

    Pfizer should also reduce their cost in administrative and advertising and pump in more resources into the research and development department so that they will be able to come up with new and improved drugs. Due to the decline in blockbuster sales and new inventions within the pipeline, it would be wise to move into more personalized treatment such as cancer. Pfizer should not only rely on the "Cash Cow "products because the industry is a now facing a shift and the one size fits all approach is not valid anymore. Pfizer should consider acquiring smaller drug companies to strengthen its portfolio since their labs are not churning out enough blockbuster products.…

    • 1041 Words
    • 5 Pages
    Great Essays